Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

3 in Phase 3

Quick facts

Phase 3 pipeline

Cardiovascular Polypill · Cardiovascular
A fixed-dose combination pill that combines multiple cardiovascular agents to reduce the risk of heart disease and stroke through complementary mechanisms including blood pressure lowering, lipid reduction, and antiplatelet effects.
FDC · Cardiovascular
FDC is a cardiovascular investigational drug developed by a Spanish research foundation, but its specific mechanism of action is not publicly disclosed.
Treatment Prevention for Secondary CV · Cardiovascular
This drug targets the PCSK9 protein to lower LDL cholesterol levels.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

What is Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III's pipeline?

Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Cardiovascular Polypill, FDC, Treatment Prevention for Secondary CV.

Sector hub: All tracked pharma companies